Study of ATG-022 plus pembrolizumab for stomach or GEJ cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combo (ATG-022 plus pembrolizumab, with or without chemo) for people with advanced stomach or gastroesophageal junction cancer that has a specific protein (CLDN 18.2) and is HER2-negative and PD-L1-positive. It may be an option if you have not had certain prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread to other parts of the body.
- Your tumor tests positive for CLDN 18.2 and PD-L1, and negative for HER2.
- You have at least one tumor that can be measured on scans.
- You have not had prior treatment with CLDN 18.2-targeted drugs or certain other therapies within the last 4 weeks.
- You have not had severe side effects from a previous immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, ATG-022, compared with standard treatments for people with advanced stomach or gastroesophageal junction cancer that has grown after at least two previous treatments. The tumor must have a specific marker called Claudin 18.2.
This trial tests a combination of two treatments: an immunotherapy drug (pembrolizumab, which helps your immune system fight cancer) and chemotherapy (FLOT) for advanced stomach or esophageal junction cancer. The goal is to see if this combination is safe and works better than standard care.
This trial tests a new immunotherapy drug called cadonilimab combined with chemotherapy for people with advanced stomach cancer that hasn't been treated yet. It compares this combination to chemotherapy with or without another immunotherapy drug, nivolumab.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This trial is testing a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as the first treatment for advanced stomach cancer. It's for people whose tumors have a specific marker called Claudin 18.2, which might make the treatment more effective.
Hear when a new Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.